Renal, cardiovascular, and safety outcomes of adding sodium-glucose cotransporter-2 inhibitors to insulin therapy in patients with type-2 diabetes: a meta-analysis.
Qian ZhangQingqing ZhangLiu YangShufang YangYu LuPublished in: International urology and nephrology (2023)
Adding SGLT2is to insulin therapy in T2DM patients showed better glucose control and decreased albuminuria, uric acid, blood pressure, and body weight without a reduction in the eGFR.
Keyphrases
- uric acid
- body weight
- blood pressure
- type diabetes
- glycemic control
- end stage renal disease
- metabolic syndrome
- small cell lung cancer
- newly diagnosed
- ejection fraction
- chronic kidney disease
- blood glucose
- prognostic factors
- epidermal growth factor receptor
- adipose tissue
- skeletal muscle
- hypertensive patients
- patient reported outcomes
- bone marrow
- mesenchymal stem cells
- smoking cessation